Get Started
To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.
Get in TouchNanoAssemblr Platform
A Disruptive Technology Enabling Transformative Medicine
Discovery
药物发现
The
NanoAssemblr®
Spark
Unmatched
Sample Recovery
Advanced microfluidics allows microliter formulation volumes with near complete sample recovery.
Intuitive Operation
Simply pipette starting materials into wells, push a button, and pipette completed formulations out.
Rapid Production
The Spark formulation process requires less than 5 seconds, allowing hundreds of formulations to be made in hours.
Robust Process
Electronic control minimizes batch-to-batch and user variability.
Workflow Integration
The Spark system is designed for operation in a sterile biosafety hood, so formulations can be made on-demand, and applied to cells in culture.
Scalable
Shared microfluidic mixing technology allows formulations to be scaled across the NanoAssemblr Platform to accelerate future development.
Preclinical
临床前研究
The
NanoAssemblr®
Ignite™
Power to Advance
Designed with the end in mind.
Designed for the future.
Designed to maximize time
Ignite replaces the Benchtop October 15, 2019
Outstanding
Reproducibility
Advanced microfluidics in an automated system removes batch-to-batch and user-to-user variability.
Intuitive Workflow
Easy setup with touch screen interface, saved recipes and a single-use fluid path that eliminates priming and cleaning enables a streamlined workflow.
Controlled Assembly
Tune particle size with precise control over fluid flow rates
Versatile
Formulate small molecules, peptides, and nucleic acids into lipid, polymer or hybrid nanoparticles, and more.
Speedy and Efficient
Formulation runs require less than a minute. Over 50 formulations can be completed in a day for rapid optimization.
Scalable
Easily scale between 1mL and 20mL formulations on the Ignite™. Optimized formulations can be predictably scaled to advanced preclinical and clinical scale with Blaze™ and GMP Systems with NxGen technology.
The
NanoAssemblr®
Blaze
The Scalable Power of NxGen
Efficient formulation for large preclinical studies, with single-mixer flow rate up to 115 mL/min with NxGen technology.
Direct path to clinic
De-risk processes by using the same NxGen microfluidic mixer on Blaze and GMP.
high range
of formulation
Formulation of 10 mL to 1L batches with the Blaze or up to 10L with the Blaze+.
Expanded Process
Development Capabilities
Optional integration to up- and downstream processes and continuous pressure monitoring.
Validation
of inline dilution
Validation of Inline Dilution.
Intuitive and easy
The signature simplicity and efficiency of the NanoAssemblr platform.
Manufacturing
制备
GMP System
Power to Commercialize
The NanoAssemblr GMP System is a modular and configurable system, fit-for-purpose and phase appropriate for the GMP manufacturing of genetic medicine.
The GMP system is a continuous flow microfluidic platform designed for scale up manufacturing
of nanoparticles under cGMP conditions. The formulation results are in sync with NanoAssemblr Ignite and Blaze-generated particles.
The Evolution of NxGen Technology
The proprietary NxGen microfluidic mixer at the heart of NanoAssemblr systems is designed exclusively for nanomedicine development. NxGen is the only technology that can scale from mL/min to L/h with the same mixer design. NxGen enables time-invariant particle formation to ensure the most reproducible results for a wide range of particle types and is capable of > 25x throughput of our Classic (formerly know as SHM) mixer.
From Bench to Commercial Scale
The NxGen mixer uses precisely controlled mixing to reproducibly generate optimal particles through a single mixer across scales.
Non-turbulent Mixing
This differs from turbulent mixing where collisions are used to speed mixing. These are extremely dependent on geometric and velocity profiles which differ at scale.
What is Nanomedicine?
Nanomedicines represent the next paradigm in drug innovation, and current research has demonstrated improved efficacy, reduced side effects and revolutionary new treatment modalities like gene therapy and targeted medicine.
Resource Center
Poster
September 01, 2022
Application Note
March 15, 2022
Publication - Abstract
July 01, 2020
Journal of Controlled Release
Publication - Abstract
May 08, 2020
Vaccines
Publication - Abstract
April 02, 2020
Journal of Controlled Release